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Summary
This is a report of the research presented at the 11th Annual Meeting of the
International Pachyonychia Congenita Consortium, held on 6 May 2014 in Albu-
querque, NM, U.S.A. This year’s meeting was divided into five corners concern-
ing pachyonychia congenita (PC) research: (i) ‘PC Pathogenesis Cornered’, an
overview of recent keratin research, for PC and other skin disorders; (ii) ‘From
All Corners of . . .’, an outline of other genetic disorders that we can learn from;
(iii) ‘Fighting For Our Corner’, an outline of National Institutes of Health/
National Institute of Arthritis and Musculoskeletal and Skin Diseases programmes
and U.S. funding opportunities applicable to rare skin disorders; (iv) ‘The PC
Corner’, focusing on recent clinical studies related to PC; and (v) ‘Clinical Corn-
ers: Turning the Corner?’, an update on ongoing PC clinical trials.
The 11th Annual Meeting of the International Pachyonychia
Congenita Consortium (IPCC) was held on 6 May 2014 in
Albuquerque, NM, U.S.A. The presentations are listed in
Table S1 (see Supporting Information). The consortium
regroups physicians and scientists who contribute their exper-
tise and time to developing therapeutics for the rare orphan
disease pachyonychia congenita (PC), an autosomal dominant
genodermatosis caused by mutations in keratins K6a, K6b,
K6c, K16 or K17.1 The main clinical features of PC include
highly debilitating pain accompanying plantar keratoderma,
hypertrophic nail dystrophy, oral leucokeratosis and epider-
mal cysts.2 Each year’s IPCC meeting is devoted to discussing
recent progress and to prioritizing future directions for PC
research.
International Pachyonychia Congenita Consortium contribu-
tions of the past 10 years include building a patient registry;
delineating the clinical manifestations of PC based on detailed
analysis of symptoms affecting patients with genetically con-
firmed PC;3 advocating for abandoning the now obsolete
descriptions Jadassohn–Lewandowsky (formerly PC type 1)
and Jackson–Lawler (formerly PC type 2) and using the new,
more rational gene-based nomenclature based on the mutated
keratin in a given patient (PC-K6a, PC-K6b, PC-K6c, PC-K16
and PC-K17);4 conducting a phase Ib clinical trial using the
mutation-specific small interfering (si)RNA TD101;5 identify-
ing sirolimus (rapamycin) as a modulator of keratin expres-
sion;6 and initiating a subsequent topical sirolimus clinical
trial for PC (update below), and publishing best practice
guidelines for PC.7
Shedding light on pachyonychia congenita
pathogenesis
Jiang Chen (Stony Brook University, NY, U.S.A.) opened
the ‘PC Pathogenesis Cornered’ section with his work on
the N159Del mutation of K75 (formerly known as K6hf),
which triggers hair and nail defects in mice.8 Chen’s group
employed an siRNA ‘sequence walk’ strategy to target the
mutated Krt75 allele, and delivered the selected candidate to
mice via a short hairpin RNA-carrying lentivirus. Their data
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demonstrate that partial interference of mutated RNA is suf-
ficient to restore the structural defects caused by a heterozy-
gous keratin mutation. These observations further strengthen
previous work with K6a,5 suggesting that a personalized
therapeutic approach to keratin disorders is clinically
relevant.
Robert Rice (University of California, Davis, CA, U.S.A.)
analysed global protein expression in tape circles from
involved and uninvolved plantar areas of patients with PC-K6a
using established techniques.9 He showed that PC skin differs
from control skin in expressing reduced levels of K9, and rela-
tively high levels of other keratins (K5, K6 and K14) and epi-
dermal differentiation markers (transglutaminases and
S100A9). A similar gene expression signature was found in
callous skin from patients with PC (collaboration with Trans-
Derm Inc., Santa Cruz, CA, U.S.A.).
Laure Rittie (University of Michigan, Ann Arbor, MI,
U.S.A.) studied the microanatomy of a PC-K16 skin biopsy
using a computer-assisted three-dimensional reconstruction
approach.10 Rittie’s group identified four defects in PC callous
skin compared with control plantar skin: epidermal blisters
and engorged blood vessels, as previously reported,11 defects
in sweat gland morphology, and fibrosis of the extracellular
matrix. An interesting group exchange followed to discuss
what sequence of events would best explain PC plantar pain
pathogenesis, and what target should be focused on for strate-
gic therapy.
Learning from other diseases
In the ‘From All Corners of. . .’ session, Paul Goldberg (Xenon
Pharmaceuticals Inc., Burnaby, Canada) presented his work
related to Nav1.7, a voltage-gated sodium channel, which
when deficient causes congenital indifference to pain. Gold-
berg reviewed his results on XEN402, an analgesic developed
to inhibit Nav1.7 that effectively alleviates peripheral neuro-
pathic pain and erythromelalgia.12,13
Eli Sprecher (Sourasky Medical Center, Tel Aviv, Israel) dis-
cussed inflammatory peeling skin syndromes including Neth-
erton syndrome (SPINK5 mutations), peeling skin syndrome
(corneodesmosin mutations) and the newly described SAM
syndrome, characterized by severe dermatitis, multiple aller-
gies and metabolic wasting [desmoglein 1 (DSG1) mutation].14
Sprecher reviewed similarities and differences in the clinical
and histological manifestations of these syndromes, all charac-
terized by epidermal barrier dysfunction.
Yong Yang (Peking University First Hospital, Beijing,
China) presented his work on Olmsted syndrome, a palmopl-
antar keratoderma accompanied by periorificial keratosis, alo-
pecia and severe itching, recently attributed to mutations of
transient receptor potential cation channel, subfamily V, mem-
ber 3 (TRPV3).15 Yang presented genotype–phenotype corre-
lation studies and proposed a biological rationale for the
severity of mild vs. mutilating forms of Olmsted syndrome.
Hans Van Bokhoven (Radboud University Medical Center,
Nijmegen, the Netherlands) closed the session by presenting
his work on p63 syndromes. Mutation of the TP63 gene causes
at least seven syndromes, triggering ectodermal dysplasia, limb
defects, orofacial clefting, or a combination of these. Van
Bokhoven showed that the ectrodactyly ectodermal dysplasia
clefting syndrome is caused by mutations affecting the
DNA-binding domain of p63. Taking advantage of the high
homology between the p63 and p53 binding domains, Van
Bokhoven’s group tested the interesting idea that the binding
function of p63 DNA could be restored utilizing a mutant
p53-targeting compound developed for cancer therapy. By
demonstrating that this was the case at least in vitro,16 these
results support the idea that a better understanding of the
pathogenesis of a genetic disease can lead to (unexpected)
therapeutic options.
Funding pachyonychia congenita research
In the last morning session, Carl Baker [National Institutes
of Health (NIH)/National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS), Bethesda, MD,
U.S.A.] reviewed the specifics of NIH/NIAMS funding
mechanisms relevant to PC, and reiterated the commitment
of NIAMS to funding research on rare skin disorders such
as PC.
Better delineating pachyonychia congenita
symptoms
‘The PC Corner’ early afternoon session summarized some
major clinical issues for patients with PC and new data from
the International PC Research Registry (IPCRR). Ilan Goldberg
(Sourasky Medical Centre, Tel Aviv, Israel) spoke about
mucosal and laryngeal leucokeratosis, which if extensive can
lead to poor feeding and, rarely, laryngeal obstruction.17
Infants and children with PC-K6a sometimes have ‘first bite
syndrome’, a severe pain anterior to the ear (probably local-
ized to the parotid gland) on first sucking or eating that lasts
about 25 s.
C. David Hansen (University of Utah, Salt Lake City, UT,
U.S.A.) discussed clinical findings of 549 individuals from
296 families with a confirmed PC genotype. Details of these
findings are updated regularly on the IPCC website (http://
www.pachyonychia.org/pc_data.php). The clinical data sup-
port a diagnostic triad of plantar pain, plantar keratoderma
and toenail dystrophy as identifying 92% of patients with PC
(excluding children aged < 3 years). The most commonly
mutated gene is KRT6A (41%), followed by KRT16 (30%),
KRT17 (17%), KRT6B (9%) and KRT6C (3%).
Barbara Hoggart (Heart of England NHS Trust, Birmingham,
U.K.) spoke about pain and PC. The differences between neu-
ropathic and nociceptive pain were discussed.18 Hoggart
reviewed preliminary data demonstrating that neuropathic
pain comprises a significant component of PC pain and varies
with genotype. The outcome of this and other studies will be
important because patients with neuropathic pain will require
a different analgesic strategy.
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Answering specifics with clinical trials
The second afternoon session, entitled ‘Clinical Trials: Turning
the Corner?’, provided an update on strategies for treatment
of the plantar pain of PC. Alain Hovnanian (Imagine Institute
and Necker Hospital, Paris, France) discussed off-label use of
capsaicin patches for plantar pain in one patient with PC. Cap-
saicin is a TRPV1 agonist that excites and then desensitizes
sensory nerves.19 Application of capsaicin patches for 30 min
produced a small-to-moderate improvement in pain, which
lasted for a few months. It was agreed that studying TRPV1
expression in PC skin would be useful.
The last three presentations were on topical sirolimus, a
mammalian target of rapamycin (mTOR) inhibitor. Sirolimus
selectively blocks translation of mRNAs with terminal oligo-
pyrimidine tracts, including KRT6 mRNA.6 Oral sirolimus
showed some promise for PC plantar pain, but use was lim-
ited by side-effects including gastrointestinal symptoms.6
Steven L. Roberds (Tuberous Sclerosis Alliance, Silver
Spring, MD, U.S.A.) spoke about the use of oral and topical
sirolimus in tuberous sclerosis complex (TSC) and the excel-
lent response of TSC facial angiofibromas to treatment. Current
challenges include a large variety of topical formulations
without head-to-head comparisons and issues with insurance
reimbursement.
Freddie Bartholomew and Viraat Patel (Stanford University,
Palo Alto, CA, U.S.A.) discussed a phase Ib randomized con-
trolled clinical trial, which has just started at Stanford, com-
paring topical sirolimus with placebo in 15 patients with PC.
The trial consists of three phases including 6 months of treat-
ment and 3 months of washout. A preliminary off-label study
in three patients showed promising results.
Roger Kaspar and Tycho Speaker (Transderm Inc., Santa
Cruz, CA, U.S.A.) discussed the good manufacturing process
formulation of topical sirolimus into a cream with an aqueous
base, which is being used in the Stanford trial. They showed
that this formulation demonstrates satisfactory stability and an
inhibitory effect on phosphorylated ribosomal protein S6, a
marker of mTOR pathway activity, in both HaCaT keratino-
cytes and mouse skin.
Conclusions
Major progress has been made in our understanding of PC
genetics and genotype–phenotype correlation, assisted greatly
by data from the IPCRR. This year’s meeting delineated prom-
ising advances in the pathophysiology of PC, including previ-
ously unknown aberrant eccrine sweat glands and blood vessel
formation, dramatic alterations of the skin proteome, and
identification of different types of pain among PC genotypes.
The intense study of many patients with focal keratoderma is
also yielding insights into those who do not have PC. The
combined efforts of the IPCC have led to a number of clinical
trials; we await with anticipation the first results of the
randomized controlled clinical trial of topical sirolimus.
Meanwhile, further planned projects were decided on,
including examining the proteome in different PC genotypes,
developing patient cell lines for collaborative studies, further
delineating neural structures and pain receptors in PC skin,
and broadening studies of both imaging and clinical pain and
sweating. All these studies were prioritized with the same aim
in mind: developing therapeutics for PC.
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